Senti Biosciences, a company developing cancer therapies using a new programmable biology platform, said it has raised $105 million in a new round of financing led by the venture arm of life sciences giant Bayer. The company’s technology uses new computational biological techniques to manufacture cell and gene therapies that can more precisely target specific … Continue reading Senti Bio raises $105 million for its new programmable biology platform and cancer therapies